Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata-Reference-Cited by-同舟云学术

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

Published:2014-07-01 Issue:7 Volume:150 Page:748
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Castela Emeline¹,Le Duff Florence²,Butori Catherine³,Ticchioni Michel⁴,Hofman Paul³,Bahadoran Philippe²,Lacour Jean-Philippe¹,Passeron Thierry⁵

Affiliation:

1. Department of Dermatology, University Hospital of Nice, Nice, France

2. Department of Dermatology, University Hospital of Nice, Nice, France2Centre de Recherche Clinique (CRC), University Hospital of Nice, Nice, France

3. Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, Nice, France

4. Laboratory of Immunology, University Hospital of Nice, Nice, France

5. Department of Dermatology, University Hospital of Nice, Nice, France5Institut National de la Santé et de la Récherche Médicale (INSERM) U1065, Team 12, Mediterranean Centre of Molecular Medicine, Nice, France

Publisher

American Medical Association (AMA)

Subject

Dermatology

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences;Journal of the European Academy of Dermatology and Venereology;2024-09-11

2. Assessment of SLEDAI score changes in systemic lupus erythematosus patients under low-dose interleukin-2 therapy: A meta-analysis;Clinical Epidemiology and Global Health;2024-09

3. Microneedle‐Mediated Delivery of Immunomodulators Restores Immune Privilege in Hair Follicles and Reverses Immune‐Mediated Alopecia;Advanced Materials;2024-06-05

4. The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review;Inflammation Research;2024-06-05

5. Translational kinetic‐pharmacodynamics of mRNA‐6231, an investigational mRNA therapeutic encoding mutein interleukin‐2;CPT: Pharmacometrics & Systems Pharmacology;2024-04-26